Chemotherapy News and Research

Latest Chemotherapy News and Research

Magnetic nanoparticles for ovarian cancer treatment

A paper published in the January issue of the journal Nanomedicine could provide the foundation for a new ovarian cancer treatment option - one that would use an outside-the-body filtration device to remove a large portion of the free-floating cancer cells that often create secondary tumors.

28 Jan 2011

Gene signature can accurately predict breast cancer outcomes

Researchers from McGill University's Rosalind and Morris Goodman Cancer Research Centre, the Research Institute of the McGill University Health Centre, the Dana-Farber Cancer Institute and Harvard Medical School have discovered a gene signature that can accurately predict which breast cancer patients are at risk of relapse, thereby sparing those who are not from the burdens associated with unnecessary treatment.

28 Jan 2011

Iniparib Phase III study in metastatic triple-negative breast cancer does not meet primary goal

Sanofi-aventis and its subsidiary, BiPar Sciences, today announced that a randomized Phase III trial evaluating iniparib (BSI-201) in patients with metastatic triple-negative breast cancer (mTNBC) did not meet the pre-specified criteria for significance for co-primary endpoints of overall survival and progression-free survival

28 Jan 2011

AB Science initiates recruitment in masitinib phase 3 study in severe persistent asthma

AB Science SA, a pharmaceutical company specialising in the research, development and commercialisation of protein kinase inhibitors (PKIs), announced today the recruitment of the first patient in the phase 3 study evaluating masitinib in severe persistent asthma.

27 Jan 2011

Healthcare at Home acquires Sciensus

Healthcare at Home Ltd, Europe's leading international provider of home-based healthcare and specialty pharmacy services, is today pleased to announce that it has acquired Sciensus Ltd, a provider of health informatics for clients across the NHS and the pharmaceutical industry.

27 Jan 2011

Targeting UROD enzyme boosts effects of radiotherapy and chemotherapy in head, neck tumors

Cancer researchers at Princess Margaret Hospital (PMH) have discovered that targeting an enzyme called Uroporphyrinogen Decarboxylase (UROD) can sensitize diseased tissue to radiation and chemotherapy, which could mean fewer side effects for individuals with head and neck cancer.

27 Jan 2011

Johnson & Johnson fourth quarter sales decreases 5.5% to $15.6 billion

Johnson & Johnson today announced sales of $15.6 billion for the fourth quarter of 2010, a decrease of 5.5% as compared to the fourth quarter of 2009. Operational sales declined 5.1% and the negative impact of currency was 0.4%. Domestic sales declined 8.1%, while international sales declined 3.1%, reflecting an operational decline of 2.3% and a negative currency impact of 0.8%.

25 Jan 2011

Emergent BioSolutions initiates TRU-016 Phase Ib/II study for chronic lymphocytic leukemia

Emergent BioSolutions Inc. today announced the initiation of a Phase Ib/II study (16201) of TRU-016 for chronic lymphocytic leukemia (CLL). TRU-016 is a CD37-directed Small Modular ImmunoPharmaceutical (SMIP™) protein therapeutic in development for the treatment of B-cell malignancies. TRU-016 is being developed in collaboration with Abbott.

25 Jan 2011

Northwest Biotherapeutics resumes enrollment in DCVax Phase II brain cancer clinical trial

Cutting edge, patient-specific vaccine treatments like DCVax® provide for a longer life expectancy along with a better quality of life for brain cancer patients, an improvement over current conventional brain tumor treatments. "The vaccine that I received has extended the median survival of Grade IV brain cancer (GBM) from 14.6 months, with conventional treatment, to over 36 months," stated Bob Gibbs, a 7 year brain cancer survivor, who has defied the odds statistically, thanks to the experimental brain cancer vaccine DCVax®.

25 Jan 2011

Study results presented at ASCO-GI reinforce value of Genomic Health's Oncotype DX Colon Cancer test

Genomic Health, Inc. today announced presentation of three studies at the American Society of Clinical Oncology Gastrointestinal Cancer Symposium, including one finding that high tumor grade was not a marker of higher recurrence risk in stage II colon cancer, suggesting that other markers, such as the Oncotype DX® Recurrence Score® (RS) test as well as T-stage and mismatch repair (MMR) status, should be considered by physicians during the treatment decision-making process.

25 Jan 2011

ASCO urges physicians, medical schools to improve quality of life for people with cancer

The American Society of Clinical Oncology today called on physicians, medical schools, insurers, and others to help improve quality of life for people with advanced cancer.

25 Jan 2011

World's largest sterile compounding center for oncology patients

Health Robotics today announced the official opening and live operation of the largest Sterile Compounding Center for Oncology patients in the world. Akdeniz University Hospital in Antalya (Turkey) compounds 90% of its 80.000 annual chemotherapy intravenous doses with 4 CytoCare robots and related Health Robotics' technology, or an average of 325 patient doses per 6-hour work cycle.

25 Jan 2011

Researchers design engineered organ study the use of nanoparticles in breast cancer detection

Purdue University researchers have reproduced portions of the female breast in a tiny slide-sized model dubbed "breast on-a-chip" that will be used to test nanomedical approaches for the detection and treatment of breast cancer.

25 Jan 2011

PediatRx announces first-ever revenues and successful launch of GRANISOL

PediatRx Inc.is pleased to provide an update on activities for the fiscal third quarter. Among its achievements, the hospital specialty pharmaceutical company reported its first-ever revenues and successfully launched GRANISOL™, the company's first commercial entry.

24 Jan 2011

Spectrum submits Post Approval Supplement for removal of bioscan requirement for Indium-111 ZEVALIN

Spectrum Pharmaceuticals, a biotechnology company with fully integrated commercial and drug development operations with a primary focus in oncology, today announced that on Thursday, January 20, 2011, it submitted a Post Approval Supplement containing data supporting the removal of the Indium-111 ZEVALIN® pre-treatment imaging evaluation, more commonly referred to as the "bioscan" requirement.

24 Jan 2011

Northwest Biotherapeutics resumes enrollment in DCVax Phase II clinical trial for GBM brain cancer

Northwest Biotherapeutics announced today that the Company is resuming enrollment of additional new patients into its ongoing 240-patient, double blind, randomized, placebo controlled Phase II clinical trial of DCVax for Glioblastoma multiforme brain cancer.

24 Jan 2011

FibroGen announces FG-3019 interim results from phase 1/2 trial against pancreatic cancer

FibroGen, today announced interim results of a phase 1/2 trial of FG-3019, a therapeutic antibody against connective tissue growth factor, in combination with gemcitabine and erlotinib in individuals with unresectable pancreatic cancer.

23 Jan 2011

Immunomedics reports encouraging results from Y-90-labeled clivatuzumab tetraxetan study in pancreatic cancer

Immunomedics, Inc., a biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases, today announced that repeated therapy cycles of its proprietary antibody, clivatuzumab tetraxetan, labeled with yttrium-90 plus low-dose gemcitabine, extended median overall survival.

21 Jan 2011

Novel FAK inhibitors targeting binding site of VEGFR-3 reduce growth of pancreatic cancer cells

CureFAKtor Pharmaceuticals, LLC, a privately-held biopharmaceutical company focused on the research and development of Focal Adhesion Kinase (FAK) inhibitors for cancer, today presented research results at the American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium in San Francisco demonstrating that novel FAK inhibitors targeting the binding site of vascular endothelial growth factor receptor 3 (VEGFR-3) reduced the growth of pancreatic cancer cells in vitro and in vivo.

21 Jan 2011

Everist Genomics reports positive results from OncoDefender-CRC assay external validation study

Everist Genomics, a prognostics company focused on developing gene-based molecular assays for the prediction of cancer recurrence, today announced the positive results of the first external validation study of its OncoDefender-CRC colorectal cancer recurrence test. The study is being conducted by Mayo Validation Support Services, and is being coordinated with investigators and resources from all three Mayo Clinic sites.

21 Jan 2011

Chemotherapy News and Research

Latest Chemotherapy News and Research

Magnetic nanoparticles for ovarian cancer treatment

Gene signature can accurately predict breast cancer outcomes

Iniparib Phase III study in metastatic triple-negative breast cancer does not meet primary goal

AB Science initiates recruitment in masitinib phase 3 study in severe persistent asthma

Healthcare at Home acquires Sciensus

Targeting UROD enzyme boosts effects of radiotherapy and chemotherapy in head, neck tumors

Johnson & Johnson fourth quarter sales decreases 5.5% to $15.6 billion

Emergent BioSolutions initiates TRU-016 Phase Ib/II study for chronic lymphocytic leukemia

Northwest Biotherapeutics resumes enrollment in DCVax Phase II brain cancer clinical trial

Study results presented at ASCO-GI reinforce value of Genomic Health's Oncotype DX Colon Cancer test

ASCO urges physicians, medical schools to improve quality of life for people with cancer

World's largest sterile compounding center for oncology patients

Researchers design engineered organ study the use of nanoparticles in breast cancer detection

PediatRx announces first-ever revenues and successful launch of GRANISOL

Spectrum submits Post Approval Supplement for removal of bioscan requirement for Indium-111 ZEVALIN

Northwest Biotherapeutics resumes enrollment in DCVax Phase II clinical trial for GBM brain cancer

FibroGen announces FG-3019 interim results from phase 1/2 trial against pancreatic cancer

Immunomedics reports encouraging results from Y-90-labeled clivatuzumab tetraxetan study in pancreatic cancer

Novel FAK inhibitors targeting binding site of VEGFR-3 reduce growth of pancreatic cancer cells

Everist Genomics reports positive results from OncoDefender-CRC assay external validation study

Cancer Research - Second Edition eBook

Transforming Lab Workflows with Cell Culture Automation

Building Bridges to Scalable Allogeneic Cell Therapy

Edoardo Fabini

Chemotherapy News and Research

Latest Chemotherapy News and Research

Cancer Research - Second Edition eBook

Transforming Lab Workflows with Cell Culture Automation

Building Bridges to Scalable Allogeneic Cell Therapy

Edoardo Fabini

Newsletters you may be interested in